Statement of Principles concerning reactive arthritis (Reasonable Hypothesis) (No. 75 of 2018)

The instrument organises a limited set of medical-legal concepts. The most important are the defined medical meaning of reactive arthritis, the list of causative or contributory factors that may raise a reasonable hypothesis linking the disease to service, temporal windows for those factors, and the requirement that any such factor be related to the person’s relevant service.

Reactive arthritis (definition)

• The instrument defines reactive arthritis as an immune-mediated arthritis of more than four weeks’ duration that is usually associated with evidence of a preceding extra-articular infection (s7(2)(a)-(b)). It explicitly excludes a list of alternative diagnoses or causes, including acute rheumatic fever, specified viral arthritides (examples given), leptospirosis, Lyme disease, post-streptococcal reactive arthritis and septic arthritis (s7(2)(c)(i)-(vi)). The Schedule cross-references the meaning (Schedule 1, reactive arthritis,see subsection 7(2)).

Temporal and diagnostic codification

• Although the Statement notes the ICD-10-AM code M02 is attracted to reactive arthritis, it specifies that the legal meaning for the purposes of the statement is the definition in s7(2) (s7(3)). An explicit reference to the edition of ICD-10-AM used is recorded (s7(4)).

Factors that will raise a reasonable hypothesis

• Section 9 lists seven disjunctive factors. The list includes specific infectious exposures within defined time windows (for example, an infection within three months before clinical onset, s9(1)), infection with HIV at clinical onset (s9(2)), recent hepatitis B vaccination (s9(3)), recent BCG therapy (s9(4)), active mycobacterial disease in the preceding 30 days (s9(5)), intestinal bypass surgery within one year (s9(6)), and inability to obtain appropriate clinical management (s9(7)). The Schedule defines "infection as specified", "BCG therapy", and "active mycobacterial disease".

Relationship to service

• The instrument requires that any factor proven be related to the person’s relevant service (s10(1)). The interplay between the inability-to-obtain-management factor and timing of the condition is constrained: s10(2) limits that factor to material contribution or aggravation where the reactive arthritis was suffered or contracted before or during (but did not arise out of) relevant service.

Cross-references and exclusions

• If any of the s9 factors refer to an injury or disease that is covered by another RMA Statement of Principles, that other Statement’s factors apply (s11). This produces an interdependence between SOPs where overlapping medical exposures or conditions are involved.

Death from reactive arthritis

• Death is included where the terminal event or condition was contributed to by the person’s reactive arthritis (s7(5)). The Schedule defines "terminal event" with specific examples such as pneumonia and cardiac arrest.

RMA’s evidentiary stance

• Section 8 records the RMA’s view that there is sound medical-scientific evidence to indicate that reactive arthritis and death from reactive arthritis can be related to relevant service. That statement provides the RMA’s foundational justification for issuing the SOP, but the instrument does not itself set evidentiary rules beyond the listed factors and definitions.

Main practical consequences

• The Statement codifies concrete temporal and exposure windows that will be decisive in raising a reasonable hypothesis. It also sets out specific exclusions and limits the application of one factor to circumstances of material contribution or aggravation when the disease pre-existed service.

Primary affected groups

• Claimants: Veterans and former members of the Australian Defence Force seeking benefits under the VEA where section 120A applies, and current or former members for MRCA claims where section 338 applies. The instrument expressly applies to claims to which s120A of the VEA or s338 of the MRCA applies (s5).
• Service categories captured: The Schedule defines "relevant service" to include operational service, peacekeeping service, hazardous service and British nuclear test defence service under the VEA and warlike or non-warlike service under the MRCA (Schedule 1, relevant service). Therefore serving and former members with exposure during those types of service are within the perimeter.

Secondary affected groups

• Medical practitioners and specialists who prepare evidence or opinions: The Statement’s definitions and temporal windows will determine what clinical findings, laboratory results and medical history are relevant. For example, proving a qualifying infection within three months (s9(1)) or hepatitis B vaccination within 30 days (s9(3)) requires documentary clinical or immunisation records.
• Decision-makers in the Department of Veterans' Affairs (DVA) and MRCA administrators: They must apply the Statement as the medical framework for raising a reasonable hypothesis in relevant claims (s3, s5, s8).
• Persons responsible for administrative evidence collection: Those preparing service records, vaccination records, treatment histories and surgical histories will need to map those documents to the Statement’s temporal thresholds.

Excluded or limited populations under the Statement

• Persons whose clinical picture falls into the exclusions listed in s7(2)(c)(i)-(vi) (for example, Lyme disease, acute rheumatic fever, specific viral arthritides) are outside the Statement’s definition of reactive arthritis even if an ICD-10-AM code M02 appears in their records. The instrument expressly states that in applying this Statement the meaning of reactive arthritis is that given in subsection 7(2) (s7(3)).

Who bears the practical burden of proof

• The instrument itself sets what must be demonstrated to raise a reasonable hypothesis: presence of at least one factor in s9, and that this factor is related to relevant service (s9, s10). The claimant will therefore need to present clinical and service evidence that corresponds to the listed factors and defined timelines. The Statement does not itself allocate the legal burden of proof but establishes the medical criteria decision-makers will use in assessing whether a reasonable hypothesis has been raised.

Who decides relevance

• The RMA produced the Statement and recorded its view about medical-scientific evidence (s3, s8). The administrative decision on a claim will be made by the relevant statutory decision-maker using this instrument as the operative medical policy. The instrument also cross-references other Statements where applicable (s11), which can affect which medical factors apply.

This Statement is a medical-legal instrument; it does not create criminal offences nor prescribe civil penalties. Its primary legal effect is to set the medical criteria used by decision-makers in determining whether a reasonable hypothesis exists connecting reactive arthritis or death from reactive arthritis to relevant service. The "duties" and "rights" that flow from the instrument are therefore administrative and evidentiary.

Duty to apply the Statement

• Decision-makers must apply this Statement of Principles when assessing relevant claims, because the instrument is determined under subsection 196B(2) of the VEA (s3) and the instrument applies to specified claims (s5). The RMA has characterised the underpinning evidence as sound medical‑scientific (s8), which is the medical basis decision-makers will apply.

Right to have the Statement applied

• A person lodging a claim that falls under s120A VEA or s338 MRCA is entitled to have that claim assessed against the Statement’s definitions and factors (s5). If a claimant can establish at least one of the factors in s9 and demonstrate its relation to their relevant service (s10), a reasonable hypothesis of service connection will be raised under the framework of this Statement.

Evidentiary requirements and duties on claimants

• To satisfy the Statement a claimant must present evidence that meets the factors in s9. For example, to rely on s9(1) the claimant must establish that they had an infection as specified within the three months before clinical onset. The Schedule’s definition of "infection as specified" narrows what infections qualify (Schedule 1).
• For s9(3) (hepatitis B vaccination within 30 days), a claimant must show vaccination within the 30-day window. For surgical history (intestinal bypass), the one-year window (s9(6)) applies.

Duty to connect factor to relevant service

• Any factor proven must be related to the person’s relevant service (s10(1)). The instrument does not specify the mechanics for proving that relationship; in practice, that link will require matching the exposure or lack of management (s9(7)) with timing and location of service in the person’s service records.

Constraints on s9(7) (inability to obtain appropriate clinical management)

• That factor may be relied upon only to support a finding of material contribution to, or aggravation of, reactive arthritis when the condition was suffered or contracted before or during relevant service, but did not arise out of the relevant service (s10(2)). In practical terms, s9(7) cannot be used to bootstrap a new condition arising out of service to the status of service-aggravated via lack of treatment; it is limited to cases where the condition pre-existed service.

Rights when a factor refers to another Statement

• If a factor in s9 refers to an injury or disease covered by another Statement, the terms of that other Statement will apply (s11). Thus a claimant and decision-maker must follow the requirements of the relevant separate Statement when assessing that factor.

No statutory penalties or offences in this instrument

• The Statement contains no punitive or enforcement provisions; its legal effect is to guide administrative determinations concerning service connection. It repeals a prior SOP (s4) and establishes new definitions and factors (s6-s11).

Administrative discretion and decision-making

• The RMA’s view of the underlying evidence is recorded (s8), but the Statement leaves evaluative assessment (for example, whether a clinical record proves an infection as specified within the relevant timeframe) to decision-makers applying the Statement within the statutory claim process. The instrument therefore shapes but does not mechanistically determine every claim outcome.

This Statement of Principles does not create criminal offences, financial penalties or a self-contained enforcement regime. Its function is administrative and evidentiary within the veterans’ benefits framework. The instrument contains no penalty provisions; it prescribes medical definitions and causation factors for use in claim assessments (s1-s11, Schedule 1).

How the Statement is enforced in practice

• Enforcement is administrative: the Statement is applied by decision-makers when determining entitlement under the VEA and MRCA claim provisions to which it applies (s5). The instrument itself does not set procedures for disputing decisions, review mechanisms, or sanctions for non-compliance; those procedural and enforcement mechanisms reside in the governing Acts and administrative processes outside this instrument.

Implications for claim assessment and potential consequences

• The practical effect of applying the Statement can be determinative of benefit outcomes: if a claimant cannot establish at least one of the factors in s9 or cannot show the factor is related to relevant service (s10), a reasonable hypothesis will not be raised and entitlement under the statutory claims pathways is unlikely to follow. Conversely, establishing a qualifying factor and relationship may be sufficient to raise a reasonable hypothesis and thereby move a claim forward. The Statement therefore functions as a gatekeeping medical standard for claims,its enforcement takes place through administrative decisions about entitlement.

Evidence quality and practitioner roles

• The Statement lists specific clinical exposures and time windows. The ability to rely upon the factors will depend on the quality of clinical records, laboratory evidence, vaccination records and service records. While the Statement records the RMA’s view of the scientific basis (s8), it delegates evaluation of documentary evidence to claim decision-makers. There is therefore an enforcement mechanism in evidence assessment rather than penalty imposition.

No sanctions for incorrect practitioner opinions

• The Statement does not prescribe sanctions against medical practitioners who provide opinions that a decision-maker may find unpersuasive. Challenges to medical findings will be handled within the administrative review and appeals processes under the VEA or MRCA, not by any enforcement mechanism in this instrument.

Relevance of cross-referenced Statements

• Section 11 requires reliance on other Statements where a factor in s9 refers to an injury or disease covered by another Statement. The administrative consequence is that decision-makers will need to apply the other Statement’s factors in addition to, or instead of, the factor text in this instrument. The Statement itself contains no direct enforcement steps beyond that cross-reference; the enforceable consequences flow from claim decisions.

Statutory basis and relationship to primary Acts

• The Statement is made under subsection 196B(2) of the VEA (s3). It applies specifically to claims to which s120A of the VEA or s338 of the MRCA applies (s5). Those references position the Statement as a medical-legal instrument that feeds into the decision-making structures and procedural provisions of the VEA and MRCA, although the instrument itself does not reproduce or amend those procedural sections.

Interaction with other Statements of Principles

• Section 11 expressly links this Statement to other SOPs: if a factor in s9 refers to an injury or disease that is already the subject of another SOP, the factors in that other SOP apply as in force from time to time. Practically, this creates an interaction where cross-covered exposures (for example, particular infections, surgical procedures or vaccinations) may be assessed under the rules of another SOP rather than, or as well as, the rules in this instrument (s11). Decision-makers must therefore coordinate application of multiple SOPs where relevant.

Use of external classification (ICD-10-AM)

• The Statement acknowledges that reactive arthritis attracts ICD‑10‑AM code M02 but directs that the legal meaning for the instrument is as given in s7(2) (s7(3)). It identifies the specific edition of ICD-10-AM referenced (Tenth Edition, effective 1 July 2017) and cites the source (s7(4)). This means diagnostic coding may be used descriptively but is not determinative where the statutory definition differs or adds exclusions.

Overlap with MRCA and VEA definitions

• The Schedule defines abbreviations MRCA and VEA and defines "relevant service" to include services under both Acts (Schedule 1). The instrument therefore sits across both legislative schemes and will be invoked where either Act’s claim provisions (s120A VEA, s338 MRCA) are in play (s5).

Replaced instrument and continuity

• The instrument expressly repeals the prior Statement of Principles concerning reactive arthritis No. 26 of 2010 (s4). Decision-makers and claimants therefore operate under the 2018 Statement for claims commencing on or after the commencement date; the precise transitional operation will be governed by the primary Acts and administrative rules, which are not reproduced here. The repeal means that prior causal windows or factor wordings in the 2010 instrument no longer apply.

No amendment or interaction with criminal law

• The Statement does not amend or interact with criminal statutes, nor does it create offences. Its interaction with other laws is limited to administrative application within the veterans’ compensation and rehabilitation frameworks and to cross-references to other SOPs and ICD coding (s3, s5, s7(3)-(4), s11, Schedule 1).

Dependence on other Statements for particular factors

• Where a factor mentions an injury or disease that itself has an SOP, the operative test will be that other SOP’s current terms (s11). This requires claim preparers and decision-makers to consult the suite of SOPs and to map factors to the correct Statement. The Statement does not provide procedural direction on how to resolve conflicts where SOPs differ; it requires the other SOPs to be applied according to their own terms.

This instrument contains its own minimal amendment history within the text provided.

Key chronological facts recorded in the instrument:

• The instrument is titled and recorded as the Statement of Principles concerning reactive arthritis (Reasonable Hypothesis) (No. 75 of 2018) (s1).
• The instrument is dated 24 August 2018 and commences on 24 September 2018 (s2 and document header).
• The instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s3).
• The instrument expressly repeals the earlier Statement of Principles concerning reactive arthritis No. 26 of 2010 (Federal Register of Legislation No. F2010L01042) previously made under the same subsection (s4).

No further amendments, modifications, or subsequent instrument changes are recorded within the text supplied. The instrument does not list any prior amendments to itself nor indicate any subsequent amendments. It does not include a schedule of transitional provisions beyond the repeal statement, nor does it specify retrospective operation beyond the commencement date.

Implications of the repeal

• The repeal (s4) signals that as from the commencement date, the 2010 Statement is no longer operative and the 2018 Statement provides the operative medical factors and definitions. The instrument does not state whether decisions under the earlier Statement are preserved, revisited or subject to transitional rules; those matters are determined by the primary Acts and administrative policy rather than by this Statement itself.

No recorded subsequent variant or erratum

• The instrument as provided contains no notes of corrigenda, replacement versions, legislative amendments, or revocations after the commencement date. The RMA’s seal and signature are present on the instrument, indicating formal determination, but the text contains no history entries beyond the date and repeal of the 2010 Statement.

Where to look for later amendments

• To determine whether the Statement has been subsequently amended or repealed after the provided date, one would consult the consolidated RMA instruments register or the Federal Register of Legislation. That step falls outside this instrument’s text; nothing in the instrument purports to record future change.

The instrument itself does not contain, cite or summarise any litigation. There are no cases or judicial decisions referenced in the Statement. The document records the RMA’s view about the soundness of medical‑scientific evidence (s8), but it does not mention any legal challenges, reviews or precedents.

What the absence of litigation references implies in this instrument

• The instrument is presented as an administrative medical determination under the VEA power; it does not purport to catalogue or summarise judicial engagement with the Statement or with reactive arthritis causation issues. The lack of litigation history in the Statement entry means the instrument does not itself identify any settled legal interpretations or contested points that have been resolved by courts. Assessors and advisers must therefore interpret the Statement’s text directly and apply it within the procedural and review frameworks of the VEA and MRCA thereafter.

Practical consequence for claim advisers

• Because the instrument contains no case law summaries or interpretive rulings, practitioners relying on it should anticipate that contested questions (for example, how strictly to construe "within three months" for s9(1) or what evidence proves "inability to obtain appropriate clinical management" under s9(7)) may be matters for administrative review or judicial review in individual cases. The Statement itself, however, provides the medical-factual thresholds a decision-maker must consider.

No named judicially-determined interpretations provided

• The instrument does not list any judicially-determined constructions of its phrases, and it does not refer to precedential rulings that would narrow or expand the meaning of its terms. Any litigation history that exists beyond the instrument’s text would have to be obtained from court records, administrative review decisions or consolidated legal databases.

This instrument contains a number of strictly worded definitions, temporal windows and exclusions that can cause claims to fail if evidence is not matched precisely. A few of the most consequential points are set out below, each grounded in the text.

Definition overrides coding (s7(2)-(4))

• Reactive arthritis is given a detailed medical definition in s7(2) and that definition is the operative legal meaning even though ICD‑10‑AM code M02 is associated with reactive arthritis (s7(3)). Practically, an ICD code on clinical records does not by itself satisfy the Statement if the clinical features fall within the listed exclusions or do not meet the duration criterion of "more than four weeks" required by s7(2)(a).

Narrow list of exclusions (s7(2)(c))

• The Statement excludes several named diagnoses and categories (for example, Ross River virus infection, Lyme disease, post-streptococcal reactive arthritis). If a claimant’s clinical picture corresponds to one of these exclusions, the Statement does not treat that condition as reactive arthritis for the purpose of raising a reasonable hypothesis.

Tight temporal windows for causative factors (s9)

• The factors have strict timing requirements: infection as specified within three months of clinical onset (s9(1)); hepatitis B vaccination within 30 days of clinical onset (s9(3)); BCG therapy within 30 days (s9(4)); active mycobacterial disease within 30 days (s9(5)); intestinal bypass surgery within one year (s9(6)). Failure to show the relevant exposure within these windows may preclude reliance on that factor.

Limited scope of "infection as specified" (Schedule 1)

• The Schedule defines "infection as specified" narrowly to include clinical or laboratory evidence of bowel infection, sexually acquired urogenital infection (excluding genital warts and herpes simplex), and infection with a specific list of organisms (Staphylococcus aureus, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis). Common infections outside this list will not qualify under s9(1) even if they temporally precede arthritis.

s9(7) is constrained (s10(2))

• The factor “inability to obtain appropriate clinical management for reactive arthritis” (s9(7)) only applies to material contribution to, or aggravation of, reactive arthritis where the reactive arthritis was suffered or contracted before or during (but did not arise out of) relevant service (s10(2)). Practically, this prevents using lack of treatment during service to support a finding that service caused a new condition unless the condition pre-existed.

Burden of proof in practice falls on claimants to document exposures and service links (s9, s10)

• The Statement requires not only proof of a qualifying factor but proof that the factor is related to relevant service (s10(1)). That means service records, deployment dates and medical records must be aligned with the factor’s timing and with the person’s clinical onset.

Cross-Statement complexity (s11)

• If a s9 factor refers to another injury or disease with its own SOP, the other SOP applies (s11). Failure to consult or satisfy the other SOP’s requirements can derail a claim that otherwise appears to meet s9.

Death claims hinge on contribution (s7(5), Schedule 1)

• Death is included only where the person’s reactive arthritis contributed to the terminal event or condition (s7(5)). The Schedule lists examples of terminal events (pneumonia, respiratory failure etc.). For death claims, medical causation evidence must link reactive arthritis to the proximate or ultimate cause of death.

Ambiguity in proof of "inability to obtain appropriate clinical management" (s9(7))

• The instrument does not define what constitutes "appropriate clinical management" or how inability to obtain it is to be evidenced. That lack of definition introduces factual uncertainty and increases the evidentiary burden on claimants to show systemic or situational barriers to treatment during the relevant period.

Vaccination/inoculation distinctions (s9(3)-(4), Schedule 1)

• The Statement allows hepatitis B vaccination as a factor (s9(3)) but separates BCG therapy as a factor (s9(4)) and defines BCG therapy in the Schedule. Practitioners should note the different time windows and the fact that BCG therapy is described as treatment rather than prophylactic vaccination; documentary evidence must be matched against the right factor text.

Duration threshold (s7(2)(a))

• The requirement that reactive arthritis be "more than four weeks' duration" may exclude presentations labelled as reactive arthritis that are shorter in duration. Attention to the documented duration of symptoms is therefore critical.

Instrument repeal effect (s4)

• Because the 2010 Statement is repealed (s4), advisers must ensure evidence is assessed against the 2018 factor wording and not the prior instrument. Differences in factor wording or timing between instruments may affect claims depending on when the relevant exposure occurred and when the claim is made.

No procedural details or evidentiary standards set here

• The Statement does not set standards for the weight to be given to types of evidence (for example, specialist opinion versus general practitioner notes), nor does it prescribe thresholds such as "balance of probabilities" within its text. Such procedural matters are governed by the parent Acts and administrative practice, not by this Statement.

For claimants, advisers and medical practitioners preparing evidence for a claim under section 120A of the VEA or section 338 of the MRCA, the Statement prescribes a clear evidence-mapping exercise. Compliance is about assembling documentary material that aligns with the Statement’s definitions, timing windows and cross-references.

Checklist of evidentiary steps, tied to the Statement

1. Confirm the claim falls within the Statement’s application:

   • Verify the claim is one to which s120A VEA or s338 MRCA applies (s5).
   • Confirm the claimant’s service falls within "relevant service" as defined in the Schedule (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike or non-warlike under the MRCA) (Schedule 1, relevant service).

2. Establish the diagnosis in the terms of the Statement:

   • Ensure the clinical diagnosis corresponds to the statutory definition in s7(2): immune-mediated arthritis of more than four weeks’ duration, usually associated with evidence of a preceding extra-articular infection, and not one of the excluded diagnoses (s7(2)(a)-(c)). Do not rely only on an ICD-10-AM code (s7(3)-(4)); map clinical findings to the statutory definition.

3. Demonstrate at least one qualifying factor in s9 with precise timing:

   • For infection as specified (s9(1)): provide clinical and laboratory evidence of a qualifying bowel, sexually acquired urogenital infection (excluding genital warts and herpes simplex), or specific organism infection (Staphylococcus aureus, Chlamydia species) within three months before clinical onset (Schedule 1, infection as specified; s9(1)). Include lab reports, microbiology, prescribed antibiotics and contemporaneous clinical notes.
   • For HIV infection (s9(2)): provide serology or specialist records showing HIV infection at the time of clinical onset.
   • For hepatitis B vaccine (s9(3)): attach immunisation records showing a hepatitis B vaccination within 30 days before clinical onset.
   • For BCG therapy (s9(4)): provide oncology/therapy records showing intravesical or intradermal BCG treatment within 30 days prior to clinical onset; Schedule 1 defines BCG therapy.
   • For active mycobacterial disease (s9(5)): provide microbiology and clinical notes confirming active tuberculosis or atypical mycobacterial disease within 30 days prior to clinical onset; Schedule 1 defines active mycobacterial disease.
   • For intestinal bypass surgery (s9(6)): supply surgical records showing the operation within one year before clinical onset.
   • For inability to obtain appropriate clinical management (s9(7)): assemble contemporaneous evidence (referrals, waitlists, operational constraints, medical facility records, correspondence) that demonstrates lack of access to appropriate care. Note s10(2) limits this factor to cases where reactive arthritis pre-existed or was contracted before/during relevant service but did not arise out of service.

4. Demonstrate relationship to relevant service:

   • Align the timing of the qualifying factor with service records, deployment dates, and locations to demonstrate that the factor is related to the person’s relevant service (s10(1)). For example, if the infection occurred while deployed on a peacekeeping mission, provide unit medical logs, field clinic records, or contemporaneous entries in service health documentation.

5. If a factor refers to another SOP, follow that SOP:

   • Where s9 references an injury or disease that is the subject of another Statement, ensure evidence also satisfies that other Statement as in force at the time (s11). Obtain and apply the other SOP’s definitions and evidentiary requirements.

6. For death claims:

   • If claiming death from reactive arthritis, provide death certificate, clinical records demonstrating reactive arthritis contributed to the terminal event, and documentation linking the reactive arthritis to the terminal event examples in the Schedule (pneumonia, respiratory failure, cardiac arrest, etc.) (s7(5); Schedule 1, terminal event).

Practical drafting and evidentiary tips

• Time-stamp everything: because the Statement uses tight time windows, dates on clinical notes, vaccination forms, surgery records and laboratory reports are crucial. If onset dates are uncertain, gather multiple concordant records and expert opinion explaining date estimation.
• Specialist opinion: obtain an opinion from a specialist (rheumatologist or infectious disease physician) that maps the clinical record to the statutory definition in s7(2), opines on whether the temporal link to the qualifying factor meets the s9 window and explains whether the reactive arthritis could have arisen from excluded causes (s7(2)(c)).
• Where infection is alleged, prefer laboratory confirmation: the Schedule allows "clinical or laboratory evidence" for infection as specified (Schedule 1), but objective microbiology or documented STI testing will be more persuasive than retrospective clinical recollection.
• For inability to obtain management (s9(7)): contemporaneous documentary evidence is gold. Where the limitation was operational (for example, theatre deployment), unit medical logs and chain-of-command statements that document the unavailability of appropriate care will assist. Remember the constraint in s10(2).
• Cross-SOP checks: create a cross-reference table showing each claimed factor, the relevant clause in this Statement (s9(x)), any other SOP implicated under s11, and the documents provided to satisfy each element.

Administrative follow-up and review

• Anticipate requests from decision-makers for further information that precisely matches the Statement’s words. Keep records and be ready to produce them promptly.
• If a decision-maker rejects a claim because a factor was outside the relevant time window or because the clinical picture fits an excluded diagnosis, consider obtaining a more detailed specialist report that addresses the particular exclusion or timing issue in terms of the statutory text.

Record-keeping and future claims

• Maintain clear copies of immunisation records, surgical records and lab tests. Because the Statement relies on precise windows, these records are often determinative years later if a claim is lodged after service.

Final note on evidentiary standard

• The Statement does not express how the statutory standard of proof is to be applied (for example, balance of probabilities) in its text; it sets out the medical factors that will raise a reasonable hypothesis. Practitioners should map their evidence to the Statement and then refer to the relevant legislative provisions and administrative guidance about the legal standard and how a reasonable hypothesis is to be treated in the claims process.